引導式測驗 · 中等 等級
攝護腺癌 MRI 之 AI 應用測驗
測試 AI 對前列腺 MRI、PI-RADS 背景、研究普遍性、臨床審查和以患者為中心的追蹤的支持。
問題 1 的 8
What can AI contribute to prostate MRI interpretation?
預覽每個問題8 問題
當您參加測驗時,就會出現答案和解釋。
- What can AI contribute to prostate MRI interpretation?
- Confirm cancer without pathology or clinical context
- Choose a biopsy treatment plan automatically
- Replace all MRI sequences with one image score
- Localize candidate lesions or support risk assessment for clinician review
- What does PI-RADS provide in prostate MRI?
- A guarantee that a detected lesion is malignant
- A laboratory quality-control requirement
- A structured framework radiologists use to describe and assess findings
- A genetic variant classification standard
- Why is prospective validation useful after a promising MRI AI study?
- It guarantees improved patient outcomes
- It tests whether performance transfers to real clinical workflows and populations
- It proves the model will work on every scanner
- It removes the need for a reference standard
- Which evidence should be used to evaluate prostate MRI AI?
- Pathology or well-defined follow-up, with relevant sensitivity and specificity measures
- Only the model’s training loss
- The number of highlighted pixels
- The clinician’s preferred image viewer
- Why can a retrospective enriched test set overstate performance?
- It has too many MRI sequences to interpret
- Pathology cannot be used as a reference
- It automatically represents every clinic
- Its patient mix may differ from the population and prevalence where the tool will be used
- How should a patient interpret an AI-highlighted prostate lesion?
- As a treatment recommendation from the model
- As a finding for radiologist and clinician assessment, not a diagnosis
- As proof that cancer is present
- As proof that biopsy is unnecessary
- What information should accompany a prostate MRI AI audit?
- Scanner and sequence protocol, software version, reader interaction, and follow-up outcomes
- Only the radiologist’s initials
- The model’s color palette
- The patient’s unrelated billing history
- Which decision belongs in shared clinical decision-making?
- The scan score overriding patient preference
- A software update setting the biopsy threshold without review
- Whether AI findings, PSA, history, and other evidence support biopsy or follow-up
- The model alone deciding treatment